Table 1.
Comparison of pathological variables according to LMP7 expression in the first consecutive breast cancer cohort
| HR+/HER2– (n=362) | HR+/HER2+ (n=42) | HR–/HER2+ (n=80) | TNBC (n=184) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytoplasmic LMP7 |
Cytoplasmic LMP7 |
Cytoplasmic LMP7 |
Cytoplasmic LMP7 |
|||||||||||||
| None | Low | High | p-value | None | Low | High | p-value | None | Low | High | p-value | None | Low | High | p-value | |
| Histologic grade | ||||||||||||||||
| 1&2 | 89 (86.4) | 94 (79.7) | 108 (76.6) | 0.156 | 6 (54.5) | 11 (73.3) | 10 (62.5) | 0.608 | 12 (52.2) | 13 (50.0) | 10 (32.3) | 0.254 | 18 (40.9) | 16 (27.1) | 18 (22.2) | 0.088 |
| 3 | 14 (13.6) | 24 (20.3) | 33 (23.4) | 5 (45.5) | 4 (26.7) | 6 (37.5) | 11 (47.8) | 13 (50.0) | 21 (67.7) | 26 (59.1) | 43 (72.9) | 63 (77.8) | ||||
| pT | ||||||||||||||||
| 1 | 43 (41.7) | 42 (35.6) | 58 (41.1) | 0.495 | 5 (45.5) | 5 (33.3) | 3 (18.8) | 0.487 | 6 (26.1) | 5 (19.2) | 7 (22.6) | 0.375 | 13 (29.5) | 13 (22.0) | 23 (28.4) | 0.084 |
| 2 | 51 (49.5) | 64 (54.2) | 72 (51.1) | 4 (36.4) | 8 (53.3) | 11 (68.8) | 11 (47.8) | 17 (65.4) | 21 (67.7) | 20 (45.5) | 37 (62.7) | 50 (61.7) | ||||
| 3 | 6 (5.8) | 10 (8.5) | 11 (7.8) | 2 (18.2) | 1 (6.7) | 2 (12.5) | 6 (26.1) | 4 (15.4) | 2 (6.5) | 5 (11.4) | 8 (13.6) | 6 (7.4) | ||||
| 4 | 3 (2.9) | 2 (1.7) | 0 | 0 | 1 (6.7) | 0 | 0 | 0 | 1 (3.2) | 6 (13.6) | 1 (1.7) | 2 (2.5) | ||||
| Lymph node metastasis | ||||||||||||||||
| Negative | 52 (51.0) | 49 (42.2) | 68 (49.6) | 0.355 | 6 (54.5) | 4 (26.7) | 4 (25.0) | 0.246 | 10 (43.5) | 10 (38.5) | 13 (41.9) | 0.959 | 18 (42.9) | 30 (50.8) | 42 (53.8) | 0.522 |
| Positive | 50 (49.0) | 67 (57.8) | 69 (50.4) | 5 (45.5) | 11 (73.3) | 12 (75.0) | 13 (56.5) | 16 (61.5) | 18 (58.1) | 24 (57.1) | 29 (49.2) | 36 (46.2) | ||||
| Tumor-infiltrating lymphocyte (%) | ||||||||||||||||
| < 10 | 88 (85.4) | 96 (81.4) | 91 (64.5) | < 0.001 | 9 (81.8) | 8 (53.3) | 10 (62.5) | 0.041 | 13 (56.5) | 11 (42.3) | 7 (22.6) | 0.003 | 22 (50.0) | 22 (37.3) | 16 (19.8) | < 0.001 |
| 10-30 | 12 (11.7) | 14 (11.9) | 30 (21.3) | 2 (18.2) | 7 (46.7) | 2 (12.5) | 6 (26.1) | 12 (46.2) | 7 (22.6) | 15 (34.1) | 16 (27.1) | 16 (19.8) | ||||
| 30-60 | 3 (2.9) | 7 (5.9) | 9 (6.4) | 0 | 0 | 4 (25.0) | 2 (8.7) | 3 (11.5) | 7 (22.6) | 5 (11.4) | 11 (18.6) | 18 (22.2) | ||||
| > 60 | 0 | 1 (0.8) | 11 (7.8) | 0 | 0 | 0 | 2 (8.7) | 0 | 10 (32.3) | 2 (4.5) | 10 (16.9) | 31 (38.3) | ||||
| HLA-ABC | ||||||||||||||||
| No | 90 (91.8) | 81 (69.2) | 36 (25.5) | < 0.001 | 8 (72.7) | 7 (46.7) | 1 (6.3) | 0.007 | 18 (78.3) | 15 (57.7) | 5 (16.1) | < 0.001 | 37 (86.0) | 16 (27.1) | 8 (9.9) | < 0.001 |
| Weak | 5 (5.1) | 22 (18.8) | 43 (30.5) | 2 (18.2) | 5 (33.3) | 8 (50.0) | 3 (13.0) | 8 (30.8) | 6 (19.4) | 2 (4.7) | 17 (28.8) | 7 (8.6) | ||||
| Strong | 3 (3.1) | 14 (12.0) | 62 (44.0) | 1 (9.1) | 3 (20.0) | 7 (43.8) | 2 (8.7) | 3 (11.5) | 20 (64.5) | 4 (9.3) | 26 (44.1) | 66 (81.5) | ||||
| MxA | ||||||||||||||||
| Low | 89 (87.3) | 92 (78.0) | 73 (51.8) | < 0.001 | 9 (90.0) | 8 (53.3) | 8 (50.0) | 0.100 | 22 (95.7) | 18 (69.2) | 14 (45.2) | < 0.001 | 34 (81.0) | 37 (62.7) | 32 (39.5) | < 0.001 |
| High | 13 (12.7) | 26 (22.0) | 68 (48.2) | 1 (10.0) | 7 (46.7) | 8 (50.0) | 1 (4.3) | 8 (30.8) | 17 (54.8) | 8 (19.0) | 22 (37.3) | 49 (60.5) | ||||
| p-eIF2a | ||||||||||||||||
| Low | 56 (55.4) | 64 (55.7) | 54 (38.6) | 0.008 | 6 (54.5) | 5 (33.3) | 3 (18.8) | 0.171 | 10 (43.5) | 9 (34.6) | 12 (38.7) | 0.772 | 23 (53.5) | 28 (47.5) | 28 (34.6) | 0.092 |
| High | 45 (44.6) | 51 (44.3) | 86 (61.4) | 5 (45.5) | 10 (66.7) | 13 (81.3) | 13 (56.5) | 17 (65.4) | 19 (61.3) | 20 (46.5) | 31 (52.5) | 53 (65.4) | ||||
| Cytoplasmic HMGB1 | ||||||||||||||||
| Low | 57 (73.1) | 65 (73.0) | 78 (66.7) | 0.543 | 5 (62.5) | 6 (50.0) | 10 (66.7) | 0.681 | 12 (63.2) | 11 (52.4) | 18 (72.0) | 0.400 | 17 (56.7) | 31 (64.6) | 31 (45.6) | 0.130 |
| High | 21 (26.9) | 24 (27.0) | 39 (33.3) | 3 (37.5) | 6 (50.0) | 5 (33.3) | 7 (36.8) | 10 (47.6) | 7 (28.0) | 13 (43.3) | 17 (35.4) | 37 (54.4) | ||||
| Cytoplasmic HMGN1 | ||||||||||||||||
| Low | 88 (87.1) | 97 (83.6) | 113 (80.1) | 0.343 | 9 (81.8) | 10 (66.7) | 13 (81.3) | 0.654 | 18 (78.3) | 16 (64.0) | 20 (64.5) | 0.464 | 38 (86.4) | 38 (64.4) | 50 (61.7) | 0.010 |
| High | 13 (12.9) | 19 (16.4) | 28 (37.9) | 2 (18.2) | 5 (33.3) | 3 (18.8) | 5 (21.7) | 9 (36.0) | 11 (35. 5) | 6 (13.6) | 21 (35.6) | 31 (38.3) | ||||
Values are presented as number (%). HR, hormone receptor, HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.